

PREGLED LITERATURE – REVIEW ARTICLE

Bronchopulmonary dysplasia: treatment and prevention

Bronhopulmonalna displazija: tretman i prevencija

Cerovic Sofija¹, Zivkovic Zorica^{1,2}, Vekovic Vesna¹, Vekovic Borko³

¹Children's Hospital for Lung Diseases and Tuberculosis, Medical Center "Dr Dragiša Mišović", Belgrade, Serbia

² Faculty of Pharmacy Novi Sad, Business Academy Novi Sad, Serbia

³Institute of Neonatology, Belgrade, Serbia

Summary Since 1967, when it was first defined and described the nature and definition of bronchopulmonary dysplasia (BPD) has evolved. Based on clinical and radiographic evidence of pulmonary disease in moderately to late premature infants with a history of respiratory distress syndrome, BPD was familiarly defined as a chronic form of lung disease in neonates treated with oxygen and positive pressure ventilation for a primary lung disorder, the nature of BPD has evolved into a "new" form of BPD typically seen in neonates surviving at the threshold of viability and characterized primarily by arrest of alveolar and vascular development. Infants develop BPD in about 1.5% of all newborn births. The incidence of BPD appears to be growing in conjunction with the increased survival of very-low-birth-weight infants who are treated for and recover from respiratory distress syndrome (RDS). This review has been an up-date of literature data, including animal studies, human pilot studies, randomized controlled trials (RCTs), meta-analyses and systematic reviews published on the PubMed data base

Key words: bronchopulmonary dysplasia, prematurity, review

Sažetak Bronhopulmonalna displazija (BPD) opisana je prvi put 1967. godine. Tadašnja definicija BPD zasnivala se na kliničkim i radiografskim znacima plućne bolesti kod prevremeno rođene dece, koja su bila na mehaničkoj ventilaciji sa pozitivnim pritiskom i dugotrajno na terapiji kiseonikom. U današnje vreme, BPD se karakteriše zastojem u razvoju alveolarnih i vaskularnih struktura kod prevremeno rođene dece. BPD se javlja u 1,5% sve novorođene dece. Incidencna BPD se povećava u skladu sa sve većim preživljavanjem prevremeno rođene dece, a posebno dece sa vrlo malom porodajnom težinom, koja su lečena i oporavila se od respiratornog distres sindroma. Ovaj rad je pregled savremene literature, uključujući studije na životinjama, u humanojoj populaciji, randomizovane kontrolisane studije, meta analize i sistematski pregled PubMed podataka.

Ključne reči: bronhopulmonalna displazija, prevremeno rođenje, pregled literature

Introduction

Since 1967, when it was first defined and described by Northway et al., the nature and definition of bronchopulmonary dysplasia (BPD) has evolved. Based on clinical and radiographic evidence of pulmonary disease in moderately to late premature infants with a history of respiratory distress syndrome, BPD was familiarly defined as a chronic form of lung disease in neonates treated with oxygen and positive pressure ventilation for a primary lung disorder (1), the nature of BPD has evolved into a "new" form of BPD typically seen in neonates surviving at the threshold of viability and characterized primarily by arrest of alveolar and vascular development (2-5).

In 2008 the National Institute of Child Health and Human Development (NIH) defined and classified BPD capturing criteria from previous definitions and incorporating a stratification system based on clinical severity by gestational age and supplemental oxygen requirement.

Infants <32 weeks postmenstrual age presenting with clinical manifestations of the disease, requiring supplemental oxygen at 28 days of life, and who were weaned to room air by 36 weeks or at discharge were considered to have mild BPD. Infants requiring <30% continuous oxygen at 36 weeks postmenstrual age or at discharge were considered to have moderate disease. Infants remaining on 30% oxygen and on continuous positive airway pressure (CPAP) were considered to have a severe form of the disease. For infants 32 weeks gestation, the identical oxygen requirement was implemented at day of life 56 (6).

Infants develop BPD in about 1.5% of all newborn births. The incidence of BPD appears to be growing in conjunction with the increased survival of very-low-birth-weight infants who are treated for and recover from respiratory distress syndrome (RDS) (7, 8).

Methods

Approximately 80 articles, including animal studies, human pilot studies, randomized controlled trials (RCTs), meta-analyses and systematic reviews published on the PubMed data base were evaluated for inclusion in this article.

DIURETICS

Furosemide (Lasix) is the treatment of choice for fluid overload in infants with BPD. Furosemide acts on the ascending loop of Henle and blocks chloride transport. Additionally, furosemide reduces interstitial edema and pulmonary vascular resistance and increases plasma oncotic pressure and lymphatic flow. It is the treatment of choice for fluid overload in BPD. Daily or alternate day furosemide therapy may ease weaning from positive pressure ventilation (PPV), oxygenation or both. Adverse effects of long-term therapy are recurrent and include hyponatremia, hypokalemia, contraction alkalosis, hypocalcemia, hypercalciuria, renal stones, nephrocalcinosis and ototoxicity. However, long-term benefits have not been established in infants with BPD (9, 10,11,12).

Thiazide diuretics plus aldosterone inhibitor have also been used in infants with BPD. In several trials of infants with BPD, thiazide diuretics combined with spironolactone increased urine output with or without upgrading in pulmonary mechanics. Hoffman et al reported that spironolactone did not reduce the need for supplemental electrolytes in preterm infants with bronchopulmonary dysplasia(13).

Overall, diuretics offer short-term enhancements in pulmonary mechanics but are related to a number of side effects that may limit longer term use (e.g., ototoxicity, electrolyte disturbances, azotemia, etc.). In addition, there are partial data demonstrating significant benefits of these agents when more expressive outcome measures are analyzed such as reduction in the duration of mechanical ventilation and hospitalization or improved long- term clinical outcomes (less asthma, pulmonary infections, etc.).

BRONCHODILATORS

Albuterol may improve lung compliance by decreasing airway resistance by relaxing smooth muscle cell. While a Cochrane review examining the role of albuterol was unable to find sufficient evidence of efficacy in the prevention of BPD, other studies have shown improvement in pulmonary mechanics following treatment (14,15). In summary, long-term efficacy has not been recognized and tolerance may develop with prolonged use.

Ipratropium bromide is a muscarinic antagonist that is related to atropine; however, it may have bronchodilator effects more potent than those of albuterol. Enhancements in pulmonary mechanics were demonstrated in patients with BPD after they received ipratropium bromide by inhalation. However, clinical trials have not demonstrated changes in the natural progression of BPD or long-term clinical respiratory status (16,17).

METHYLXANTHINES

Caffeine treatment for the prevention of apnea of prematurity and BPD is currently the standard of care in most neonatal intensive care units. (18) Methylxanthines are used to increase respiratory drive, decrease apnea, and improve diaphragmatic contractility. These substances may also decrease pulmonary vascular resistance and increase lung compliance in infants with BPD, probably by directly causing smooth muscle to relax.

Schmidt et al. conducted a large, multicenter RCT investigating the effects of caffeine on apnea of prematurity in a cohort of infants weighing 500–1250 g at birth (19). Less BPD, patent ductus arteriosus (PDA), and cerebral palsy when followed out to 18–21 months corrected gestational age (20) did not translate into longer-term benefits when this same cohort of infants was examined at 5 years of age (21).

VITAMIN A

Vitamin A is important in maintaining cell integrity and promoting tissue repair with deficiencies producing significant changes in the tracheobronchial tree (22). Multiple studies have demonstrated that very low birth weight infants are deficient in Vitamin A and at a propensity to develop BPD (23, 24).

Seven trials of vitamin A supplementation in preterm neonates to prevent BPD were analyzed for the Cochrane Collaborative Neonatal review. Vitamin A supplementation reduced BPD and death at 36 weeks' postmenstrual age.

CORTICOSTEROIDS

Systemic and inhaled corticosteroids have been studied extensively in preterm infants to prevent and treat BPD.

Dexamethasone is the primary systemic synthetic corticosteroid studied in preterm neonates. This drug stabilizes cell and lysosomal membranes, increases surfactant synthesis, increases serum vitamin A concentration, inhibits prostaglandin and leukotriene, decreases pulmonary edema (PE), breaks down granulocyte aggregates, and improves pulmonary microcirculation. Its adverse effects are hyperglycemia, hypertension, weight loss, GI bleeding or perforation, cerebral palsy, adrenal suppression, and death.

Papile et al. stated that early use of dexamethasone during the first 2 weeks of life did not prevent BPD and may worsen neurologic outcome (25). Infants who received a combination of dexamethasone and indomethacin were at enlarged risk of spontaneous intestinal perforation. Neurodevelopmental follow-up studies of infants treated with prolonged and high-dose dexamethasone suggest that long-term outcome appears to considerably worsen.

Inhaled steroids have been observed as a therapeutic approach to the treatment of BPD in order to promote respiratory benefits while reducing systemic side effects. Studies examining the benefits of inhaled corticosteroids administered early or late have not been able to validate any effect of inhaled corticosteroids on short-term respiratory outcomes or longer-term clinical respiratory status (26, 27).

Additionally, inhaled corticosteroids appear to offer no clinical advantage over systemic steroid therapy (28).

VASODILATORS

Infants with BPD can experience intermittent episodes of hypoxia which can promote secondary pulmonary vasoconstriction and pulmonary hypertension, adding to the complexity of BPD (29, 30). This has caused much interest in the selective pulmonary vasodilator nitric oxide (NO) as alterations in NO signaling, vascular growth, and reactivity appear to play a role in the development of BPD (31, 32). Multiple randomized controlled trials of iNO in preterm infants have been performed using varying entry criteria and outcomes. The results are mixed.

Ballard et al demonstrated a modest but statistically significant benefit in survival without BPD at 36 weeks PMA. (33) Evidence from Van Meurs et al. indicate a high rate of mortality and intraventricular hemorrhage (IVH) in infants weighing <1000 g at birth who received inhaled NO (34). Large meta-analyses have been unable to find steady long-term improvement in mortality or the incidence and severity of BPD when using inhaled NO in preterm infants as a prevention or rescue therapy (35, 36).

LATE SURFACTANT

Surfactant replacement was established as an effective and safe therapy for immaturity-related surfactant deficiency by the early 1990s (37). Systematic reviews of randomized, controlled trials confirmed that surfactant administration in preterm infants with established respiratory distress syndrome (RDS) reduces mortality, decreases the incidence of pulmonary air leak (pneumothoraces and pulmonary interstitial emphysema) and lowers the risk of chronic lung disease or death at 28 days of age (38,39,40). Subsequent trials indicated that prophylactic or early administration of surfactant resulted in fewer pneumothoraces, less pulmonary interstitial emphysema, and improved survival without BPD (41,42,43,44). However, recent randomized clinical trials indicate that the benefits of prophylactic surfactant are no longer evident in groups of infants when continuous positive airway pressure (CPAP) is used routinely (45,46,47).

ANTIOXIDANTS

Different antioxidant strategies are under development in order to prevent and treat respiratory diseases of prematurity, particularly with the scope of BPD prevention, since present preventive strategies and medical treatment are certainly suboptimal. Melatonin (MT) has been poorly explored for this indication as far as now, but encouraging results were obtained in preterm newborns and animal models, indicating melatonin induced suppression of oxidative stress (OS) pathways and upregulation of antioxidant enzymes (AOEs). These data suggest that MT may be considered as an appreciated candidate for future researches in this field. Recent evidence also suggests potential protective effects of AOE's supplementation or overexpression against OS induced lung injury. However, only a minority of available data were obtained from clinical

settings; therefore larger clinical trials are mandatory in order to clarify therapeutic potentials of such strategies.

Conclusion

BPD is a complex multisystem disease that carries a important physical, social, and economic burden for the survivors and their families. While multiple therapies are used regularly either alone or in combination (potentially increasing drug-drug interactions and associated side effects), there is lack of evidence supporting short and longer-term use of many of these agents. In fact, no single therapy has been shown to have a significant impact on the incidence or severity of BPD. Future research should be aimed at establishing better biomarkers predictive of BPD and associated longer-term chronic respiratory morbidity, developing models to identify high-risk infants earlier, and applying a multimodal approach when studying various pharmacologic interventions.

References

1. Northway WH, Rosan RC, Porter DY. Pulmonary Disease Following Respirator Therapy of Hyaline-Membrane Disease. *NEJM* 1967; 276:357-368.
2. Husain AN, Siddiqui NH and Stocker JT. Pathology of development in postsurfactant bronchopulmonary dysplasia. *Hum Pathol* 1998; 29: 710-717. doi:10.1016/S0046-8177(98)90280-5
3. Jobe AJ. The new BPD: an arrest of lung development. *Pediatr Res* 1999; 46:641-643. doi:10.1203/00006450-199912000-00007
4. Jobe AH and Bancalari. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2001; 163: 1723-1729. doi:10.1164/ajrccm.163.7.2011060
5. Baraldi E and Filippone M. Chronic lung disease after premature birth. *NEJM* 2007; 357: 1946-1955. doi:10.1056/NEJMra067279
6. Cerny L, Torda JS, Rehan VK. Prevention and treatment of bronchopulmonary dysplasia: contemporary status and future outlook. *Lung* 2008;186(2):75-89.
7. Tin W, Wiswell TE. Adjunctive therapies in chronic lung disease: examining the evidence. *Semin Fetal Neonatal Med* 2008;13(1):44-52.
8. Ambalavanan N, Carlo W. Ventilatory strategies in the prevention and management of bronchopulmonary dysplasia. *Semin Perinatol* 2006;30(4):192-199.
9. Rush MG, Engelhardt B, Parker RA and Hazinski TA. Double-blind, placebo-controlled trial of alternate day furosemide therapy in infants with chronic bronchopulmonary dysplasia. *J Pediatr* 1990; 117: 112-118. doi: 10.1016/S0022-3476(05)82458-8
10. Sahni J and Phelps S. Nebulized furosemide in the treatment of bronchopulmonary dysplasia in preterm infants. *J Pediatr Pharmacol Ther* 2011; 16: 14-22. doi: 10.1002/14651858.CD001453
11. Stewart A and Brion LP. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease.

- Cochrane Data base Syst Rev 2011; 9:CD001453. doi:10.1002/14651858.CD001453.pub2
12. Segar JL. Neonatal diuretic therapy: furosemide, thiazides and spironolactone. *Clin Perinatol* 2012; 39: 209–220. doi:10.1016/j.clp.2011.12.007
 13. Hoffman DJ, Gerdes JS and Abbasi S. Pulmonary function and electrolyte balance following spironolactone treatment in preterm infants with chronic lung disease: a double-blind, placebo-controlled randomized trial. *J Perinatol* 2000; 20, 41–45. doi:10.1038/sj.jp.7200307.
 14. Robin B, Kim Y J, Huth J, Klocksieben J, Torres M, Tepper RS et al. Pulmonary function in bronchopulmonary dysplasia. *Pediatr Pulmonol* 2004; 37: 236–242. doi:10.1002/ppul.10424
 15. Ng G, Da Silva O and Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. *Cochrane Database Syst Rev* 2012;6:CD003214. doi:10.1002/14651858.CD003214.pub2
 16. De Boeck K, Smith J, Van Lierde S and Devlieger H. Response to bronchodilators in clinically stable 1-year-old patients with bronchopulmonary dysplasia. *Eur J Pediatr* 1998; 157, 75–79. doi:10.1007/s004310050771
 17. Pantalitschka T and Poets CF. Inhaled drugs for the prevention and treatment of bronchopulmonary dysplasia. *Pediatr Pulmonol* 2006; 41: 703–708. doi: 10.1002/ppul.20467
 18. Ghanta S, Leeman KT and Christou H. An update on pharmacologic approaches to bronchopulmonary dysplasia. *Semin Perinatol* 2013; 37: 115–123. doi: 10.1053/j.semperi.2013.01.008
 19. Schmidt B, Roberts RS, Davis P, Doyle L, Barrington KJ, Ohlsson A et al. Caffeine therapy for apnea of prematurity. *NEJM* 2006; 354: 2112–2121. doi:10.1056/NEJMoa054065
 20. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A et al. Long-term effects of caffeine therapy for apnea of prematurity. *NEJM* 2007;357, 1893–1902. doi:10.1056/NEJMoa073679
 21. Schmidt B, Anderson PJ, Doyle LW, Dewey D, Grunau RE, Asz-talos EV, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. *JAMA* 2012;307: 275–282. doi: 10.1001/jama.2011.2024
 22. Anzano MA, Olson JA and Lamb AJ. Morphologic alterations in the trachea and the salivary gland following the induction of rapid synchronous vitamin A deficiency in rats. *Am J Pathol.* 1980; 98: 717–732.
 23. Shenai JP, Rush MG, Stahlman MT and Chytil F. Plasmaretinol-binding protein response to vitamin A administration in infants susceptible to bronchopulmonary dysplasia. *J. Pediatr.* 1990; 116: 607–614. doi:10.1016/S0022-3476(05)81614-2
 24. Darlow BA and Graham PJ. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants. *Cochrane Data base Syst Rev* 2011; 10:CD000501. doi: 10.1002/14651858.CD000501.pub3
 25. Papile LA, Tyson JE, Stoll BJ, et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. *N Engl J Med.* 1998; Apr 16. 338(16):1112-8.
 26. Onland W, Offringa M and van Kaam A. Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. *Cochrane Database Syst. Rev.* 2012; 4:CD002311
 27. Shah VS, Ohlsson A, Halliday HL and Dunn M. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. *Cochrane Database Syst Rev* 2012; 5:CD001969. doi: 10.1002/14651858.CD001969.pub3
 28. Shah SS, Ohlsson A, Halliday HL and Shah VS. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. *Cochrane Database Syst Rev* 2012; 5:CD002058. doi: 10.1002/14651858.CD002058.pub2
 29. Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. *Pediatrics* 2007; 120, 1260–1269. doi:10.1542/peds.2007-0971
 30. Steinhorn RH. Diagnosis and treatment of pulmonary hypertension in infancy. *Early Hum Dev* 2013; 89, 865–874. doi:10.1016/j.earlhumdev.2013.09.012
 31. MacRitchie AN, Albertine KH, Sun J, Lei PS, Jensen SC, Freestone AA et al. Reduced endothelial nitric oxide synthase in lungs of chronically ventilated preterm lambs. *Am J Physiol Lung Cell Mol Physiol* 2001; 281, L1011–L1020.
 32. Afshar S, Gibson LL, Yuhanna IS, Sherman TS, Kerecman JD, Grubb PH et al. Pulmonary NO synthase expression is attenuated in a fetal baboon model of chronic lung disease. *Am J Physiol Lung Cell Mol Physiol* 2003; 284, L749–L758.
 33. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill, JD et al. NOCLD Study Group. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. *NEJM* 2006; 355, 343–353. doi: 10.1056/NEJMoa061088
 34. Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK et al. Inhaled nitric oxide for premature infants with severe respiratory failure. *NEJM* 2005; 353, 13–22. doi: 10.1056/NEJMoa043927
 35. Askie LM, Ballard RM, Cutter GR, Dani C, Elbourne D, Field D. et al. Inhaled nitric oxide in preterm infants: an individual patient-data meta-analysis of randomized trials. *Pediatrics* 2011; 128, 729–739. doi:10.1542/peds.2010-2725
 36. Donahue PK, Gilmore MM, Cristofalo E, Wilson RF, Weiner JZ, Lau BD. Inhaled nitric oxide in preterm infants: a systematic review. *Pediatrics* 2011; 127, e414–e422. doi:10.1542/peds.2010-3428
 37. Engle WA. American Academy of Pediatrics Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. *Pediatrics.* 2008;121(2):419–432. doi:10.1542/peds.2008-1214-432
 38. Soll RF. Synthetic surfactant for respiratory distress syndrome in preterm infants. *Cochrane Database Syst Rev.* 2000;(2):CD001149. doi:10.1002/14651858.CD001149
 39. Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. *Cochrane Database Syst Rev* 2009; (2):CD007836. doi:10.1002/14651858.CD007836
 40. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. *Cochrane Database Syst Rev* 2001; (2):CD000144. doi:10.1002/14651858.CD000144
 41. (2):CD000144. doi:10.1002/14651858.CD000144
 42. Rojas-Reyes MX, Morley CJ, Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. *Cochrane Database Syst Rev* 2012;3(3):CD000510. doi:10.1002/14651858.CD000510
 43. Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. *Cochrane Database Syst Rev* 2007;(4):CD003063. doi:10.1002/14651858.CD003063
 44. Bahadue FL, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. *Cochrane Database Syst Rev* 2012;11(11):CD001456. doi:10.1002/14651858.CD001456
 45. Soll R, Ozek E. Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants.

- Cochrane Database Syst Rev 2010;
(1):CD001079pmid:20091513
46. Pfister RH, Soll R, Wiswell TE. Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev 2009; (4):CD006180pmid:19821357
47. Rev. 2009; (4):CD006180pmid:19821357
48. Soll R, Ozek E Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2009; (1):CD000141pmid:19160177
49. Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2000; (2):CD000511pmid:10796380

Primljeno/Received: 13. 08. 2016.

Prihvaćeno/Accepted: 15. 09. 2016.

Correspondance to:

Sofija Cerović
cerovicsofija@yahoo.com
